View Financial HealthAmoéba 配当と自社株買い配当金 基準チェック /06Amoéba配当金を支払った記録がありません。主要情報n/a配当利回りn/aバイバック利回り総株主利回りn/a将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • Apr 16Amoéba and Koppert Highlight the Potential of Axpera Technology in Brazil for Strategic CropsAmoéba, industrial greentech specialised in the development of natural microbiological solutions based on the patented use of amoebae, announces that it has conducted, in partnership with Koppert, an extensive programme of field trials in Brazil to assess the potential of its AXPERA biofungicide technology on several key crops, such as soya and orange trees, of which Brazil is the world’s leading producer. The visit, which took place at the end of March, demonstrated the promising results of the trials and confirmed the Brazilian market’s interest in Amoéba. With regard to soya, the trial programme conducted with several contractors in various production regions has confirmed the promising performance of AXPERA, under conditions of moderate to high pressure from Asian rust. These results are all the more remarkable given that AXPERA was tested under real-world farming conditions, as a complement to a standard fungicide programme and against a backdrop of high expectations among technicians for a multi-site biofungicide in the face of the growing risk of soybean rust resistance to chemical fungicides. As for orange trees, the initial results observed against bacterial canker appear encouraging and could, in the long term, help reduce the use of copper, given the known risks of bioaccumulation in the soil. These trials conducted in Brazil, which form part of the strategic agreement signed with Koppert in June 2025, thus confirm the full potential of AXPERA technology on crops such as soya and citrus, complementing the European and American markets where the two companies focus on vines and vegetable crops. On the strength of these initial results, Amoéba is considering the potential commercialisation of its technology in Brazil in 2028, once the following steps have been completed: Obtaining approval from the Brazilian authorities, a process falling under the remit of three ministries. The Ministry of Health has already confirmed that the AXPERA product poses no risk. The Ministries of the Environment and Agriculture are currently reviewing the product for its first targeted use against soya rust, with approval currently expected in 2027. Applications to extend the authorisation to new uses will then be submitted for strategic crops and diseases defined jointly with Koppert; Final confirmation of the marketing positioning following a new trial campaign to be carried out in 2027, in other regions representative of soya and orange cultivation.Price Target Changed • Apr 14Price target decreased by 15% to €1.10Down from €1.30, the current price target is provided by 1 analyst. New target price is 29% above last closing price of €0.86. Stock is down 12% over the past year. The company is forecast to post a net loss per share of €0.075 next year compared to a net loss per share of €0.14 last year.お知らせ • Mar 26Amoéba S.A. has filed a Follow-on Equity Offering in the amount of €4 million.Amoéba S.A. has filed a Follow-on Equity Offering in the amount of €4 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 5,333,333 Price\Range: €0.75 Transaction Features: Subsequent Direct ListingNew Risk • Mar 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of French stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€3.5m free cash flow). Negative equity (-€14m). Shareholders have been substantially diluted in the past year (39% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (7.5% average weekly change). Market cap is less than US$100m (€63.4m market cap, or US$73.5m).Breakeven Date Change • Sep 04Forecast to breakeven in 2027The 3 analysts covering Amoéba expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 15% per year to 2026. The company is expected to make a profit of €550.0k in 2027. Average annual earnings growth of 57% is required to achieve expected profit on schedule.New Risk • Jul 29New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 39% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€4.8m free cash flow). Negative equity (-€10m). Shareholders have been substantially diluted in the past year (39% increase in shares outstanding). Revenue is less than US$1m (€602k revenue, or US$696k). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€100k net loss in 3 years). Share price has been volatile over the past 3 months (10% average weekly change). Market cap is less than US$100m (€58.3m market cap, or US$67.4m).Price Target Changed • Jul 25Price target decreased by 10% to €1.30Down from €1.45, the current price target is an average from 2 analysts. New target price is 53% above last closing price of €0.85. Stock is up 94% over the past year. The company is forecast to post a net loss per share of €0.13 next year compared to a net loss per share of €0.13 last year.Board Change • Jul 08High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. No experienced directors. 1 highly experienced director. Director Valerie Filiatre is the most experienced director on the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.お知らせ • May 22Amoéba S.A., Annual General Meeting, Jun 26, 2025Amoéba S.A., Annual General Meeting, Jun 26, 2025. Location: 38 avenue des freres montgolfier, chassieu FranceNew Risk • Apr 23New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of French stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€4.8m free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Negative equity (-€10m). Revenue is less than US$1m (€602k revenue, or US$681k). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€100k net loss in 3 years). Market cap is less than US$100m (€51.8m market cap, or US$58.7m).Price Target Changed • Apr 16Price target increased by 57% to €1.26Up from €0.80, the current price target is an average from 2 analysts. New target price is 29% above last closing price of €0.98. Stock is up 152% over the past year. The company is forecast to post a net loss per share of €0.13 next year compared to a net loss per share of €0.29 last year.New Risk • Jun 06New major risk - Negative shareholders equityThe company has negative equity. Total equity: -€3.9m This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€13m free cash flow). Negative equity (-€3.9m). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€5.8m net loss in 2 years). Shareholders have been diluted in the past year (7.2% increase in shares outstanding). Market cap is less than US$100m (€24.3m market cap, or US$26.4m).お知らせ • May 25Amoéba S.A., Annual General Meeting, Jun 27, 2024Amoéba S.A., Annual General Meeting, Jun 27, 2024. Location: 38 avenue des freres montgolfier, chassieu FranceNew Risk • Sep 17New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (120% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Currently unprofitable and not forecast to become profitable over next 3 years (€900k net loss in 3 years). Share price has been volatile over the past 3 months (9.0% average weekly change). Market cap is less than US$100m (€27.0m market cap, or US$28.7m).New Risk • Sep 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (120% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Currently unprofitable and not forecast to become profitable over next 3 years (€900k net loss in 3 years). Share price has been volatile over the past 3 months (9.0% average weekly change). Market cap is less than US$100m (€28.4m market cap, or US$30.7m).New Risk • Jul 13New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of French stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (105% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€100k net loss in 3 years). Share price has been volatile over the past 3 months (7.9% average weekly change). Market cap is less than US$100m (€31.3m market cap, or US$34.9m).Price Target Changed • Jul 12Price target increased by 51% to €1.09Up from €0.72, the current price target is provided by 1 analyst. New target price is 61% above last closing price of €0.68. Stock is up 29% over the past year. The company posted a net loss per share of €0.24 last year.Board Change • Nov 16Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. Director Pierre Armand Morgon was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.分析記事 • Oct 14Amoéba (EPA:ALMIB) Is Carrying A Fair Bit Of DebtWarren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Board Change • Aug 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. Director Pierre Armand Morgon was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Jul 02Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. Director Pierre Armand Morgon was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.分析記事 • Apr 28Is Amoéba (EPA:ALMIB) A Risky Investment?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...分析記事 • Oct 20Does Amoéba (EPA:ALMIB) Have A Healthy Balance Sheet?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...分析記事 • Apr 29Does Amoéba (EPA:ALMIB) Have A Healthy Balance Sheet?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Is New 90 Day High Low • Feb 18New 90-day low: €2.53The company is down 29% from its price of €3.57 on 20 November 2020. The French market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is down 3.0% over the same period.Is New 90 Day High Low • Nov 20New 90-day high: €3.57The company is up 32% from its price of €2.70 on 21 August 2020. The French market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is flat over the same period.Is New 90 Day High Low • Sep 29New 90-day low: €1.55The company is down 47% from its price of €2.95 on 01 July 2020. The French market is down 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 7.0% over the same period.決済の安定と成長配当データの取得安定した配当: ALMIBの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: ALMIBの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Amoéba 配当利回り対市場ALMIB 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (ALMIB)n/a市場下位25% (FR)2.0%市場トップ25% (FR)5.5%業界平均 (Chemicals)2.2%アナリスト予想 (ALMIB) (最長3年)n/a注目すべき配当: ALMIBは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: ALMIBは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: ALMIBの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: ALMIBが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YFR 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/11 07:23終値2026/05/11 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Amoéba S.A. 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。6 アナリスト機関Andrew KeenEdison Investment ResearchGuy SipsKBC Securities NVThomas VrankenKBC Securities NV3 その他のアナリストを表示
お知らせ • Apr 16Amoéba and Koppert Highlight the Potential of Axpera Technology in Brazil for Strategic CropsAmoéba, industrial greentech specialised in the development of natural microbiological solutions based on the patented use of amoebae, announces that it has conducted, in partnership with Koppert, an extensive programme of field trials in Brazil to assess the potential of its AXPERA biofungicide technology on several key crops, such as soya and orange trees, of which Brazil is the world’s leading producer. The visit, which took place at the end of March, demonstrated the promising results of the trials and confirmed the Brazilian market’s interest in Amoéba. With regard to soya, the trial programme conducted with several contractors in various production regions has confirmed the promising performance of AXPERA, under conditions of moderate to high pressure from Asian rust. These results are all the more remarkable given that AXPERA was tested under real-world farming conditions, as a complement to a standard fungicide programme and against a backdrop of high expectations among technicians for a multi-site biofungicide in the face of the growing risk of soybean rust resistance to chemical fungicides. As for orange trees, the initial results observed against bacterial canker appear encouraging and could, in the long term, help reduce the use of copper, given the known risks of bioaccumulation in the soil. These trials conducted in Brazil, which form part of the strategic agreement signed with Koppert in June 2025, thus confirm the full potential of AXPERA technology on crops such as soya and citrus, complementing the European and American markets where the two companies focus on vines and vegetable crops. On the strength of these initial results, Amoéba is considering the potential commercialisation of its technology in Brazil in 2028, once the following steps have been completed: Obtaining approval from the Brazilian authorities, a process falling under the remit of three ministries. The Ministry of Health has already confirmed that the AXPERA product poses no risk. The Ministries of the Environment and Agriculture are currently reviewing the product for its first targeted use against soya rust, with approval currently expected in 2027. Applications to extend the authorisation to new uses will then be submitted for strategic crops and diseases defined jointly with Koppert; Final confirmation of the marketing positioning following a new trial campaign to be carried out in 2027, in other regions representative of soya and orange cultivation.
Price Target Changed • Apr 14Price target decreased by 15% to €1.10Down from €1.30, the current price target is provided by 1 analyst. New target price is 29% above last closing price of €0.86. Stock is down 12% over the past year. The company is forecast to post a net loss per share of €0.075 next year compared to a net loss per share of €0.14 last year.
お知らせ • Mar 26Amoéba S.A. has filed a Follow-on Equity Offering in the amount of €4 million.Amoéba S.A. has filed a Follow-on Equity Offering in the amount of €4 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 5,333,333 Price\Range: €0.75 Transaction Features: Subsequent Direct Listing
New Risk • Mar 19New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of French stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€3.5m free cash flow). Negative equity (-€14m). Shareholders have been substantially diluted in the past year (39% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (7.5% average weekly change). Market cap is less than US$100m (€63.4m market cap, or US$73.5m).
Breakeven Date Change • Sep 04Forecast to breakeven in 2027The 3 analysts covering Amoéba expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 15% per year to 2026. The company is expected to make a profit of €550.0k in 2027. Average annual earnings growth of 57% is required to achieve expected profit on schedule.
New Risk • Jul 29New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 39% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€4.8m free cash flow). Negative equity (-€10m). Shareholders have been substantially diluted in the past year (39% increase in shares outstanding). Revenue is less than US$1m (€602k revenue, or US$696k). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€100k net loss in 3 years). Share price has been volatile over the past 3 months (10% average weekly change). Market cap is less than US$100m (€58.3m market cap, or US$67.4m).
Price Target Changed • Jul 25Price target decreased by 10% to €1.30Down from €1.45, the current price target is an average from 2 analysts. New target price is 53% above last closing price of €0.85. Stock is up 94% over the past year. The company is forecast to post a net loss per share of €0.13 next year compared to a net loss per share of €0.13 last year.
Board Change • Jul 08High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. No experienced directors. 1 highly experienced director. Director Valerie Filiatre is the most experienced director on the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
お知らせ • May 22Amoéba S.A., Annual General Meeting, Jun 26, 2025Amoéba S.A., Annual General Meeting, Jun 26, 2025. Location: 38 avenue des freres montgolfier, chassieu France
New Risk • Apr 23New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of French stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€4.8m free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Negative equity (-€10m). Revenue is less than US$1m (€602k revenue, or US$681k). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€100k net loss in 3 years). Market cap is less than US$100m (€51.8m market cap, or US$58.7m).
Price Target Changed • Apr 16Price target increased by 57% to €1.26Up from €0.80, the current price target is an average from 2 analysts. New target price is 29% above last closing price of €0.98. Stock is up 152% over the past year. The company is forecast to post a net loss per share of €0.13 next year compared to a net loss per share of €0.29 last year.
New Risk • Jun 06New major risk - Negative shareholders equityThe company has negative equity. Total equity: -€3.9m This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€13m free cash flow). Negative equity (-€3.9m). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€5.8m net loss in 2 years). Shareholders have been diluted in the past year (7.2% increase in shares outstanding). Market cap is less than US$100m (€24.3m market cap, or US$26.4m).
お知らせ • May 25Amoéba S.A., Annual General Meeting, Jun 27, 2024Amoéba S.A., Annual General Meeting, Jun 27, 2024. Location: 38 avenue des freres montgolfier, chassieu France
New Risk • Sep 17New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (120% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Currently unprofitable and not forecast to become profitable over next 3 years (€900k net loss in 3 years). Share price has been volatile over the past 3 months (9.0% average weekly change). Market cap is less than US$100m (€27.0m market cap, or US$28.7m).
New Risk • Sep 01New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (120% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Currently unprofitable and not forecast to become profitable over next 3 years (€900k net loss in 3 years). Share price has been volatile over the past 3 months (9.0% average weekly change). Market cap is less than US$100m (€28.4m market cap, or US$30.7m).
New Risk • Jul 13New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of French stocks, typically moving 7.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (105% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€100k net loss in 3 years). Share price has been volatile over the past 3 months (7.9% average weekly change). Market cap is less than US$100m (€31.3m market cap, or US$34.9m).
Price Target Changed • Jul 12Price target increased by 51% to €1.09Up from €0.72, the current price target is provided by 1 analyst. New target price is 61% above last closing price of €0.68. Stock is up 29% over the past year. The company posted a net loss per share of €0.24 last year.
Board Change • Nov 16Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. Director Pierre Armand Morgon was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
分析記事 • Oct 14Amoéba (EPA:ALMIB) Is Carrying A Fair Bit Of DebtWarren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
Board Change • Aug 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. Director Pierre Armand Morgon was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Jul 02Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. No highly experienced directors. Director Pierre Armand Morgon was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
分析記事 • Apr 28Is Amoéba (EPA:ALMIB) A Risky Investment?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
分析記事 • Oct 20Does Amoéba (EPA:ALMIB) Have A Healthy Balance Sheet?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
分析記事 • Apr 29Does Amoéba (EPA:ALMIB) Have A Healthy Balance Sheet?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Is New 90 Day High Low • Feb 18New 90-day low: €2.53The company is down 29% from its price of €3.57 on 20 November 2020. The French market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is down 3.0% over the same period.
Is New 90 Day High Low • Nov 20New 90-day high: €3.57The company is up 32% from its price of €2.70 on 21 August 2020. The French market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is flat over the same period.
Is New 90 Day High Low • Sep 29New 90-day low: €1.55The company is down 47% from its price of €2.95 on 01 July 2020. The French market is down 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 7.0% over the same period.